Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VECTRA-01 AZD2265 vs Standard of Care in PSMA-positive mCRPC (Japan Safety Run-in + Phase 3)
jRCT2071260035Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- Jul 2026
- Modality
- Small Molecules
01
Overview
Phase 3, randomised trial in metastatic castration-resistant prostate cancer (mCRPC) comparing AZD2265 monotherapy with Standard-of-care therapy (2 arms). Primary endpoints: Safety (Japan Safety Run-in Sub-study), Radiographic Progression-Free Survival (rPFS) and 1 more. Started Jul 2026; status: recruiting.
02
Drugs
palacaparib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on jRCT2071260035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071260035.